Roche Diabetes Care

What Roche Diabetes Care does

Roche Diabetes Care is the diabetes care division of F. Hoffmann-La Roche Ltd, a Swiss multinational healthcare company founded in 1896 in Basel. The division operates with nearly 50 years of experience in diabetes care, offering a portfolio under the Accu-Chek and mySugr brands that spans blood glucose meters, test strips, insulin delivery systems, and mobile-app-based digital diabetes management. Underlying this portfolio is the Integrated Personalised Diabetes Management (iPDM) platform, which connects hardware devices (Bluetooth-enabled glucometers and insulin pens) with software (the mySugr app and data analytics) to enable continuous data flow among people with diabetes, caregivers, and healthcare providers.

The division generates revenue primarily through hardware and consumables sales (glucose meters, test strips, insulin delivery systems) sold directly to consumers via pharmacies and online channels, through healthcare providers and clinics, and via digital-first distribution through the mySugr app platform. A secondary, recurring/subscription revenue stream comes from the mySugr digital health platform. Customer segments include individuals living with diabetes (primary), their caregivers (secondary), and physicians, diabetes educators, and healthcare systems (primary clinical channel). The division competes in the global CGM and blood glucose monitoring market alongside Abbott Diabetes Care, Dexcom, Medtronic, and Tandem Diabetes Care, and serves virtually every market worldwide through the Roche Group's distribution infrastructure.

Roche Diabetes Care holds the 5th-largest CGM calibration patent portfolio globally and continues to invest in R&D for connected care, evidenced by 2025 partnerships in Asia Pacific across India, China, Japan, Singapore, and Vietnam, and clinical validation work such as a multi-center study in India demonstrating HbA1c reduction from 8.8% to 7.5% when pairing the Accu-Chek Instant with the mySugr app. The division operates with 5,001-10,000 employees and reports financials only at the consolidated F. Hoffmann-La Roche Ltd level.

Name

Roche Diabetes Care

Legal name

F. Hoffmann-La Roche Ltd

Website

https://rochediabetes.com

Company type

Private

Founded year

1896

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Roche Diabetes Care, a division of F. Hoffmann-La Roche Ltd, develops and markets the Accu-Chek glucose monitoring portfolio and mySugr digital platform under its Integrated Personalised Diabetes Management (iPDM) framework, serving people with diabetes, caregivers, and healthcare providers globally.

Ownership category

akta.pro rank

Product category

Blood Glucose Monitoring & Diabetes Management Devices

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Custom Computer Programming Services (541511)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)

akta.pro secondary industries

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Patch Pumps & Wearable Insulin Delivery (HLAHAHAC), Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL), Diabetes (General) (HLAKADAA)

Keywords

• Blood glucose monitoring
• Diabetes management systems
• Continuous glucose monitoring
• Insulin delivery systems
• Digital diabetes platform

Headquarters

HQ city

Burgdorf

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device and Consumables Sales: Revenue generated from glucose monitoring devices, test strips, insulin delivery systems, and related consumables sold to people with diabetes, healthcare providers, and caregivers
2. Digital Health Solutions: Digital applications and software platforms including mySugr app services for diabetes management

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Roche Diabetes Care develops, manufactures, and sells blood glucose monitoring systems (under the Accu-Chek brand), insulin delivery systems, and digital diabetes management solutions (including the mySugr mobile app). Its offerings are unified through the Integrated Personalised Diabetes Management (iPDM) platform that combines connected meters, consumable test strips, and software to support people with diabetes and their care teams.

Product overview

Roche Diabetes Care offers a unified portfolio of diabetes management solutions built around two primary brands: Accu-Chek (glucose monitoring hardware including Bluetooth-enabled meters and test strips) and mySugr (digital health app for connected data management and tracking). These products are integrated through the Integrated Personalised Diabetes Management (iPDM) platform, which connects glucose monitoring, insulin delivery, and digital solutions to enable seamless data flow between patients, caregivers, and healthcare providers. The portfolio is designed to address the full diabetes care journey from initial diagnosis through ongoing management.

Differentiator

Problem solved

Functional benefit

Brands

• Accu-Chek: Brand for glucose monitoring devices, insulin delivery systems, and related diabetes care products including the Accu-Chek Instant glucometer
• mySugr

Products and services

• Accu-Chek blood glucose meters (e.g., Accu-Chek Instant, Accu-Chek Guide, Accu-Chek Mobile)

Quantifiable outcome

• HbA1c reduction from 8.8% to 7.5% in type 2 diabetes patients using Accu-Chek Instant with mySugr app over 3 months

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Strategic Partners in Asia PacificcoreStrategic or Co-development Partner · 1 January 2025Roche Diabetes Care is expanding its presence in the Asia Pacific digital diabetes management market through strategic partnerships and product launches, with key market players including Roche, Dexcom, Medtronic, Abbott, and Tandem Diabetes Care competing in this high-growth region.
• Patent Ecosystem Partners (Abbott, Medtronic MiniMed, Dexcom, University of Padua)coreTechnology or Integration · 1 January 2007Roche Diabetes Care is identified as one of five principal assignees in the CGM calibration patent landscape, indicating significant technology development and potential cross-licensing relationships within the diabetes technology ecosystem. The company holds approximately 5th position among major patent filers in this space.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Dexcom: Dexcom is a leading pure-play continuous glucose monitor manufacturer competing head-to-head with Roche's diabetes portfolio. It is one of the five principal CGM calibration patent assignees and a direct competitor in glucose monitoring, with a much narrower product focus than Roche Diabetes Care.
• Abbott Diabetes Care: Abbott's Diabetes Care division produces the FreeStyle Libre CGM and related BGM products, directly overlapping Roche's Accu-Chek and iPDM offerings. It is named alongside Roche as one of the top five CGM calibration patent filers, making it one of the closest direct competitors.
• LifeScan (OneTouch): LifeScan markets the OneTouch brand of blood glucose meters and test strips, directly competing with Accu-Chek in the BGM category. It serves similar patient and HCP segments and historically has been one of Roche's primary BGM competitors globally.
• Medtronic Diabetes: Medtronic's Diabetes division offers integrated insulin pumps, CGM sensors (Guardian), and closed-loop systems (MiniMed). It competes directly with Roche's insulin delivery and glucose monitoring portfolio and is one of the five principal CGM patent assignees identified alongside Roche.
• Ascensia Diabetes Care: Ascensia produces the Contour blood glucose monitoring portfolio and competes directly with Accu-Chek in BGM meters, test strips, and increasingly connected diabetes solutions. Both companies target similar patient and HCP segments across global markets.
• Tandem Diabetes Care: Tandem makes insulin pumps (t:slim, t:sport) with integrated CGM connectivity, competing in the insulin delivery and connected diabetes management space alongside Roche's portfolio. It is identified as one of the key Asia Pacific digital diabetes management competitors.

Broad incumbents

• Novo Nordisk: Novo Nordisk is the global leader in insulin and broader diabetes pharmaceuticals, with growing connected device and digital health initiatives. It overlaps with Roche's diabetes ecosystem as a broader incumbent player in diabetes care, though primarily through therapeutics rather than BGM hardware.
• Sanofi Diabetes: Sanofi is a major diabetes pharmaceutical manufacturer (insulins, GLP-1s) with growing digital diabetes management efforts. It competes with Roche Diabetes Care at the broader diabetes care level and is identified among major competitors in Asia Pacific digital diabetes management markets.

Regional players

• Ypsomed: Ypsomed is a Swiss-based manufacturer of insulin delivery systems and pen needles serving European and select global markets. It competes with Roche's insulin delivery portfolio, particularly in Europe where Roche Diabetes Care is headquartered.

Emerging players

• Insulet Corporation: Insulet's Omnipod patch pump competes in the wearable insulin delivery category that overlaps with Roche's insulin delivery offerings. As a focused patch-pump innovator, it represents a more specialized competitor in insulin delivery rather than full-stack diabetes management.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/roche
• YouTubeyoutube.com/roche
• Facebookfacebook.com/roche
• LinkedInlinkedin.com/company/roche
• Instagraminstagram.com/roche

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Diabetes Care